Verici Dx (VRCI) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 saw strong momentum with Tutivia testing volumes up 32% quarter-on-quarter and 34% year-on-year, surpassing management expectations.

• Seven new transplant centres began ordering tests, with a second centre integrating Tutivia into clinical protocols.

• Repeat ordering centres increased, with six centres growing volumes by over 20% and two of the largest by over 30%.

• Tutivia now covers 20% of annual US kidney transplants based on UNOS.org data.

Outlook and guidance

• Management expresses confidence in achieving further commercial traction throughout 2026 and beyond, supported by ongoing business development.

• Full year results for 2025 will be announced by the end of May 2026.

Segment performance

• Tutivia testing volumes reached 392 in Q1 2026, up from 296 in Q4 2025.

• Average reimbursement rates remain in line with expectations.